<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To review insulin detemir for clinical use to better manage patients with type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A MEDLINE search, in English, from June 30, 2006 to December 1, 2008, using the terms "insulin analogs," "insulin detemir" and "long-acting insulin analog." RESULTS: Insulin detemir improves glycemic control, based on HbA(1C) reduction and fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> levels, without increasing the risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and <z:mp ids='MP_0005456'>weight gain</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Insulin detemir has lower glycemic variability, with less intra-subject variability in blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels in patients with type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, without increasing the risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>When added to oral anti-<z:mp ids='MP_0002055'>diabetes</z:mp> agents (OADs) in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, insulin detemir demonstrates superiority to other basal insulin options </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSION: Insulin detemir appears to provide better glycemic control with a lower risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and less <z:mp ids='MP_0005456'>weight gain</z:mp> in the treatment of patients with type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>